Demographic and histopathological features of patients with primary bladder cancer without recurrence in two-year follow-up.
To investigate the demographic characteristics associated with bladder cancer recurrence..
The retrospective study was conducted at the Urology Clinic of İzmir Katip Çelebi University Atatürk Training and Research Hospital, Turkiye, and comprised data from 2013 to 2017 related to patients who received intravesical treatment in the early postoperative period and did not show recurrence in at least two years of follow up. Patients with non-recurrent primary bladder cancer were placed in group A, while patients with recurrent bladder cancer tumours who underwent transurethral bladder tumour resection and received a single dose of intravesical therapy were placed in group B. Demographic and clinical characteristics of all the patients were noted in detail. Data was analysed using SPSS 25.
Of the 118 patients, 67(56.8%) were in group A; 56(83.6%) males and 11(16.4%) females with mean age 63.5±10.3 years. There were 51(43.2%) patients in group B; 44(86.3%) males and 7(13.7%) females with mean age 66.5±10.4 years (p>0.05). The median follow-up time in group A was 24 months (interquartile range: 24-48 months) and it was 24 months (interquartile range: 6-108 months) in group B (p=0.336). There were significant intergroup differences in terms of occupational distributions, living place, exposure to carcinogenic substances, use of plastic ware, six weeks of maintenance intravesical therapy, daily water intake, and coffee consumption (p<0.05).
A number of factors were identified that may have a role in ensuring recurrence-free survival among bladder cancer patients.
The retrospective study was conducted at the Urology Clinic of İzmir Katip Çelebi University Atatürk Training and Research Hospital, Turkiye, and comprised data from 2013 to 2017 related to patients who received intravesical treatment in the early postoperative period and did not show recurrence in at least two years of follow up. Patients with non-recurrent primary bladder cancer were placed in group A, while patients with recurrent bladder cancer tumours who underwent transurethral bladder tumour resection and received a single dose of intravesical therapy were placed in group B. Demographic and clinical characteristics of all the patients were noted in detail. Data was analysed using SPSS 25.
Of the 118 patients, 67(56.8%) were in group A; 56(83.6%) males and 11(16.4%) females with mean age 63.5±10.3 years. There were 51(43.2%) patients in group B; 44(86.3%) males and 7(13.7%) females with mean age 66.5±10.4 years (p>0.05). The median follow-up time in group A was 24 months (interquartile range: 24-48 months) and it was 24 months (interquartile range: 6-108 months) in group B (p=0.336). There were significant intergroup differences in terms of occupational distributions, living place, exposure to carcinogenic substances, use of plastic ware, six weeks of maintenance intravesical therapy, daily water intake, and coffee consumption (p<0.05).
A number of factors were identified that may have a role in ensuring recurrence-free survival among bladder cancer patients.